about
Computer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challengesDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsThe Role of Interaction Model in Simulation of Drug Interactions and QT ProlongationQuantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.Serum potassium, sodium and calcium levels in healthy individuals - literature review and data analysis.Plasma vs heart tissue concentration in humans - literature data analysis of drugs distribution.Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept.Artificial neural networks as an engine of Internet based hypertension prediction tool.Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.Model of the distribution of diastolic left ventricular posterior wall thickness in healthy adults and its impact on the behavior of a string of virtual cardiomyocytes.Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.Slow delayed rectifying potassium current (IKs ) - analysis of the in vitro inhibition data and predictive model development.Wild type and K897T polymorphisms of the hERG gene: modeling the APD in Caucasians.Circadian models of serum potassium, sodium, and calcium concentrations in healthy individuals and their application to cardiac electrophysiology simulations at individual levelPopulation-based mechanistic prediction of oral drug absorptionA four-compartment PBPK heart model accounting for cardiac metabolism - model development and application.The impact of pharmaceutical care on patients with hypertension and their pharmacists.In vitro-in vivo extrapolation of drug-induced proarrhythmia predictions at the population level.Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity.Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.From Heuristic to Mathematical Modeling of Drugs Dissolution Profiles: Application of Artificial Neural Networks and Genetic Programming.Early Drug Discovery Prediction of Proarrhythmia Potential and Its CovariatesHumans Vary, So Cardiac Models Should Account for That Too!Assessment of inter-individual variability in predicted phenytoin clearance.Antibacterial drug prescription for outpatients: age, seasonal and pulmonary disease dependency.BDTcomparator: a program for comparing binary classifiers.Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models.Virtual population generator for human cardiomyocytes parameters: in silico drug cardiotoxicity assessment.The effects of six antipsychotic agents on QTc--an attempt to mimic clinical trial through simulation including variability in the population.QTc modification after risperidone administration--insight into the mechanism of action with use of the modeling and simulation at the population level approach.Quantitative Assessment of the Physiological Parameters Influencing QT Interval Response to Medication: Application of Computational Intelligence Tools.Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development.Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals[Usefulness of some databases in medical practice]Analysis of non-hospital antibacterial pharmacotherapy in PolandArtificial neural network in pharmacoeconomicshERG in vitro interchange factors--development and verificationEnhanced QSAR models for drug-triggered inhibition of the main cardiac ion currentsIn vitro to human in vivo translation - pharmacokinetics and pharmacodynamics of quinidineDrug-physiology interaction and its influence on the QT prolongation-mechanistic modeling study
P50
Q26861453-5806647E-EB13-43DD-98EF-79C9EC52BEE8Q28071256-76A4C6C4-4274-4DA0-A445-50E078D0C3F1Q28077218-11B30C8F-B209-4EFA-8695-76207838979DQ30669399-4CE8FF55-CDDB-4250-B54A-785F32014468Q30882622-91F1C3B9-8D29-4817-9B18-364D357167C2Q30909481-2FD42F30-8A85-41CB-98E3-C439E6EA1E29Q31140927-15CE4889-059D-4BA6-B147-93225CF46B66Q33212535-3053D75C-D4B0-481D-A927-BDD9E496C7CEQ33383073-7E622CCD-7BE2-43B0-A572-31315ACE9C5BQ33901445-162229A4-E1DB-4337-BE79-7A31ED997E39Q34116212-D3480E9B-DACB-409D-9494-C218F60C2531Q34159048-0ECCEFC5-AE25-4489-921F-5FB5C6D90AFEQ36469348-D3FF12FF-A418-4FD9-AE73-8B3A8C026E88Q37178051-B97D231D-1EEB-493B-9C65-F387B69BCF0EQ37214520-E376D3E0-2840-4821-A678-594DAEDEDE9CQ37554425-BC8CACBE-1CCF-4D80-8BA6-A748CE46E65EQ37672532-0E7DA3DA-9551-4FD5-80EA-DF4CAC5CD138Q38154048-EA01B879-A1BC-4F70-8B9E-8F0DBCDA8BB2Q38975462-4E1DEF50-58A5-456D-8AC9-905A6E5B05E4Q39320298-3BC02095-203C-4BE0-8FC0-3FB29818D83CQ41763840-9794FC58-C62A-420D-A2B8-7F9891933D0CQ41772724-4CED190B-7BC6-436B-AB93-8647133F5C06Q42077295-2A3CBE75-0B56-49DC-B2A1-38AAED21F5C9Q43299753-55397277-5126-4C7B-8F17-C8DA12706428Q45572343-44CE9831-7A8F-421E-8221-E1B23C40B392Q45773345-68B4993C-7361-4567-970C-86239899AFDCQ47343072-A7F6A874-7E3F-4FD9-A780-17A0194C23C0Q48564860-A0C7E720-F11F-4AD6-92D3-DFD07118DF43Q50801726-0F77D420-022F-4FC1-9885-C143894E075AQ50921804-1F7AFF5C-4B3B-45B0-B96B-32849F7FB4D6Q51734499-88DA6488-A9DA-4432-BC7E-6C25286D9C31Q55095974-7B15181B-8990-4ECE-B551-D925B4297213Q57142642-B17C6067-C83C-45AE-ACE5-8624D5264653Q74621680-E0DF242D-E71D-452A-B09A-957930042192Q81098192-646DF19E-27E5-4F38-8E77-8F7CE18D39B9Q81415313-1A72D8D3-61BE-4647-80B7-38CC4C7E8B65Q84584534-5D83ED28-2A33-49EA-A567-60297F3FA5E6Q86457119-E86B0A78-2D4A-41DC-8B1C-A4FEE0963263Q87105720-C2C5710D-A518-492E-8DF3-C2C060468B6AQ88076451-F53F84FB-D249-4089-A793-85CDF6B6F63E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sebastian Polak
@ast
Sebastian Polak
@en
Sebastian Polak
@es
Sebastian Polak
@nl
Sebastian Polak
@pl
Sebastian Polak
@sl
type
label
Sebastian Polak
@ast
Sebastian Polak
@en
Sebastian Polak
@es
Sebastian Polak
@nl
Sebastian Polak
@pl
Sebastian Polak
@sl
prefLabel
Sebastian Polak
@ast
Sebastian Polak
@en
Sebastian Polak
@es
Sebastian Polak
@nl
Sebastian Polak
@pl
Sebastian Polak
@sl
P106
P1153
8206238600
P1559
Sebastian Polak
@pl
P21
P2456
P2798
P31
P3124
P3829
P496
0000-0001-8614-0642